The identification of genetic abnormalities in lung cancer and their consequences for cell growth, differentiation and function offer insights into normal cellular function and carcinogenesis. The integration of this knowledge with data from other fields, including epidemiology, toxicology, carcinogen metabolism, clinical genetics and clinical cancer therapy, promises advancements in lung cancer risk assessment, screening, prevention, prognostic assessment and therapy.